...
首页> 外文期刊>Journal of clinical psychopharmacology >Improvement in subjective and objective neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study
【24h】

Improvement in subjective and objective neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study

机译:重度抑郁症患者主观和客观神经认知功能的改善:一项为期12周的多肽田奈汀与依他普仑随机试验,CAMPION研究

获取原文
获取原文并翻译 | 示例
           

摘要

Although many patients with major depressive disorder (MDD) complain of neurocognitive impairment, the effects of antidepressant medications on neurocognitive functions remain unclear. This study compares neurocognitive effects of tianeptine and escitalopram in MDD. Patients with MDD (N = 164) were randomly assigned in a 1:1 ratio to either tianeptine (37.5 mg/d) or escitalopram (10 mg/d) for 12 weeks. Outcome measures included clinical improvement, subjective cognitive impairment on memory and concentration, the Mini-Mental State Examination, the Continuous Performance Test, the Verbal Learning Test, and the Raven Progressive Matrices, assessed every 4 weeks. After 12 weeks, the tianeptine group showed significant improvement in commission errors (P = 0.002), verbal immediate memory (P < 0.0001), Mini-Mental State Examination (P < 0.0001), delayed memory (P < 0.0001), and reasoning ability (P = 0.0010), whereas the escitalopram group improved in delayed memory and reasoning ability but not in the other measures. Both groups significantly improved in subjective cognitive impairment in memory (P < 0.0001) and concentration (P < 0.0001). Mixed effects model repeated measures analyses revealed that the tianeptine group had a significant improvement in scores of commission errors (F = 6.64, P = 0.011) and verbal immediate memory (F = 4.39, P = 0.038) from baseline to 12 weeks, compared with the escitalopram group, after controlling for age, sex, education years, baseline scores, and changes of depression severity. The treatment of MDD with tianeptine led to more improvements in neurocognitive functions, especially in commission errors and verbal immediate memory, compared with escitalopram, after controlling for changes in depression severity. Both drugs improved subjective cognitive impairment of memory and concentration.
机译:尽管许多患有重度抑郁症(MDD)的患者抱怨神经认知功能受损,但抗抑郁药对神经认知功能的影响仍不清楚。这项研究比较了替丁汀和依他普仑在MDD中的神经认知作用。 MDD(N = 164)患者以1:1的比例随机分配至替丁汀(37.5 mg / d)或依他普仑(10 mg / d),持续12周。结果指标包括每4周评估一次的临床改善,对记忆力和注意力的主观认知障碍,小精神状态检查,持续表现测验,言语学习测验和乌鸦进步矩阵。 12周后,替丁汀组在佣金错误(P = 0.002),口头即时记忆(P <0.0001),小精神状态检查(P <0.0001),延迟记忆(P <0.0001)和推理能力方面显示出显着改善(P = 0.0010),而依他普仑组在延迟记忆和推理能力上有所改善,但在其他方面则没有改善。两组的记忆力(P <0.0001)和注意力(P <0.0001)的主观认知障碍均得到显着改善。混合效果模型重复测量分析显示,从基线到12周,天肽组在佣金错误评分(F = 6.64,P = 0.011)和口头即时记忆(F = 4.39,P = 0.038)方面有显着改善,与依他普仑组在控制了年龄,性别,受教育年限,基线得分和抑郁严重程度的变化之后。在控制抑郁症严重程度的变化之后,与依西酞普兰相比,使用噻庚定治疗MDD可以使神经认知功能得到更大的改善,尤其是在佣金错误和言语立即记忆方面。两种药物均能改善记忆力和注意力的主观认知障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号